Pages that link to "Q37642538"

The following pages link to Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine (Q37642538):

Displaying 46 items.

• Safety of human papillomavirus vaccines: a review (Q28082119) (← links)
• The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil (Q28251070) (← links)
• Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study (Q28300023) (← links)
• Safety of human papillomavirus vaccines: a review. (Q33162724) (← links)
• Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects (Q33411345) (← links)
• Adverse events following immunization in Ontario's female school-based HPV program (Q33412759) (← links)
• Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial (Q34199560) (← links)
• Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever (Q34322342) (← links)
• Towards the eradication of HPV infection through universal specific vaccination (Q34812959) (← links)
• Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccines (Q35038292) (← links)
• Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial (Q35886910) (← links)
• Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa (Q35887646) (← links)
• Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice (Q35927665) (← links)
• Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males (Q36270681) (← links)
• Monitoring human papillomavirus prevalence in urine samples: a review (Q36694308) (← links)
• Review of Gardasil (Q36949778) (← links)
• Answering human papillomavirus vaccine concerns; a matter of science and time (Q36952972) (← links)
• Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008-2010. (Q37015871) (← links)
• Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (Q37802641) (← links)
• Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women (Q37818140) (← links)
• The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. (Q37912062) (← links)
• Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women† (Q37937705) (← links)
• Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine (Q37942643) (← links)
• Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study (Q37996715) (← links)
• A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18 (Q38006991) (← links)
• Factors impacting HPV vaccination: lessons for health care professionals (Q38223242) (← links)
• Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts (Q38229304) (← links)
• Present status of human papillomavirus vaccine development and implementation (Q38460201) (← links)
• The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases (Q38555725) (← links)
• 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. (Q38586257) (← links)
• Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in (Q38655630) (← links)
• The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus (Q38839706) (← links)
• Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. (Q42198414) (← links)
• A Blinded Comparison of Injection Pain With Quadrivalent Human Papilloma Virus Vaccine Versus Other Vaccines (Q45340148) (← links)
• Bad news: The influence of news coverage and Google searches on Gardasil adverse event reporting (Q47358311) (← links)
• Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial (Q47573076) (← links)
• Safety of Human Papillomavirus Vaccines: An Updated Review (Q49564347) (← links)
• 9-Valent human papillomavirus vaccine: a review of the clinical development program (Q49687633) (← links)
• HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks. (Q55053063) (← links)
• Analytical performance of a low-cost multiplex polymerase chain reaction human papillomavirus genotyping assay for use in Sub-Saharan Africa. (Q57038462) (← links)
• HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature (Q58548278) (← links)
• Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination (Q64132124) (← links)
• Invited Commentary: Moving From Evidence to Impact for Human Papillomavirus Vaccination-The Critical Role of Translation and Communication in Epidemiology. (Q64992588) (← links)
• Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up (Q91027633) (← links)
• Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA (Q93188907) (← links)
• Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study (Q102387844) (← links)